Literature DB >> 33298904

Novel COL4A1 mutations identified in infants with congenital hemolytic anemia in association with brain malformations.

Hiromi Ogura1, Shouichi Ohga2, Takako Aoki1, Taiju Utsugisawa1, Hidehiro Takahashi3, Asayuki Iwai4, Kenichiro Watanabe5, Yusuke Okuno6, Kenichi Yoshida7, Seishi Ogawa7,8,9, Satoru Miyano10, Seiji Kojima11, Toshiyuki Yamamoto12, Keiko Yamamoto-Shimojima13,14, Hitoshi Kanno1.   

Abstract

Genetic causes of undiagnosed hemolytic anemia in nineteen patients were analyzed by whole-exome sequencing, and novel COL4A1 variants were identified in four patients (21%). All patients were complicated with congenital malformations of the brain, such as porencephaly or schizencephaly. In these patients, hemolysis became less severe within 2 months after birth, and red cell transfusion was no longer required after 50 days, whereas chronic hemolysis continued.

Entities:  

Year:  2020        PMID: 33298904      PMCID: PMC7695726          DOI: 10.1038/s41439-020-00130-w

Source DB:  PubMed          Journal:  Hum Genome Var        ISSN: 2054-345X


Congenital hemolytic anemia is caused by genetic abnormalities of the red cell membrane, enzyme, or hemoglobin. We have been performing research studies on congenital hemolytic anemia. As a result, extensive analyses of hemoglobin, red cell membrane, and enzymes have been performed. However, approximately 40% of patients remained undiagnosed (personal data). Recently, we encountered infantile patients with hemolytic anemia in whom novel COL4A1 variants were identified. Here, detailed information on the patients and the identified variants is reported. This study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the institution. After receiving written an informed consent from the patients’ families, we obtained blood samples from patients and their parents. Genomic DNA was extracted using a standard protocol. Using trio samples, whole-exome sequencing (WES) was performed, as described previously[1]. The extracted data were mapped to a reference genome (GRCh37/hg19), annotated, and filtered in accordance with the method described previously[1]. The possible candidate variants were reconfirmed by Sanger sequencing. Nineteen infants with undiagnosed congenital hemolytic anemia were included in this study. Immunological hemolysis, unstable hemoglobinopathies, red cell membrane defects and red cell enzymopathies were ruled out by routine laboratory tests, including direct a antiglobulin test, isopropanol test, osmotic fragility test, eosin 5′-maleimide binding test, acidified glycerol lysis time, and reduced glutathione and 15 red blood cell enzyme activities. Through WES, four novel COL4A1 missense variants were identified among 19 patients with undiagnosed infantile hemolytic anemia (4/19 = 21%): NM_001845.6:c.2354G>T [p.Gly785Val], c.2537G>A [p.Gly846Glu], c.2788G>A [p.Gly930Ser] and c.2843G>A [p.Gly948Asp] (Table 1). In the WES data, there were no other possible candidate variants related to hemolytic anemia. The identified COL4A1 variants were reconfirmed by Sanger sequencing. According to the ACMG recommendation, all variants were evaluated as “pathogenic” or “likely pathogenic”[2].
Table 1

Results of this study.

Case 1Case 2Case 3Case 4
Mutationchr13:110831374chr13:110830500chr13:110829313chr13:110829258
NM_001845.6:c.2354G>TNM_001845.6:c.2537G>ANM_001845.6:c.2788G>ANM_001845.6:c.2843G>A
p.Gly785Valp.Gly846Glup.Gly930Serp.Gly948Asp
CADD_phred23.124.13524.3
ACMG criteriaPS1, PS2, PM2, PP3, and PP4PS2, PM2, PP3, and PP4PS2, PM2, PP3, and PP4PS2, PM2, PM5, PP3, and PP4
InterpretationPathogenicLikely pathogenicLikely pathogenicPathogenic
Inheritancede novode novode novode novo
GenderMFFF
Age (month)0223
Family history
Period of gestation (week)39373537
Birth weight (g)2190246716242336
Test day (day)04781115
Hb (g/dL)9.36.86.77.4
MCV (fL)1279911090
MCHC (%)31.431.929.932.7
Retics (%)16.49.214ND
LDH (U/L)582302242847
Hp (mg/dL)1<10<7.1<10
Osmotic fragilityNDNDND
EMA (% of Ct)ND87.698.194.2
RBC morphologyNormalPoikilocytesShizocytesAnisocytes
Icterus gravis neonatorum+++
Last blood transfusion date (day)6504551
Splenomegaly
Phototherapy+++
Exchange blood transfusion7 times
Improvement of anemia++++
OthersMicrocephaly, paraventricular calcification, cataractSchizencephaly, cataract, macroglossiaMicrocephaly, porencephaly with paraventricular carcificationHydrocephaly, epidermolysis bullosa

EMA eosin 5′-maleimide, ND not detected

Results of this study. EMA eosin 5′-maleimide, ND not detected Clinical information on the patients is also summarized in Table 1. All patients were born with low birth weight in association with moderate to severe neonatal hemolytic anemia. The prenatal medical histories of all patients were not remarkable. Morphological changes in the peripheral blood smear were observed in three patients (Cases 2, 3, and 4). All patients showed spontaneous remission of hemolytic anemia within 2 months after birth and no longer required red cell transfusion after 50 days. All patients were complicated with congenital anomalies in the central nervous system, such as porencephaly or schizencephaly. In 2005, COL4A1 was identified as a causative gene for hereditary porencephaly[3]. Variants in COL4A1 have been shown to be associated with a broad range of disorders, including small-vessel brain disease of various severities, including polencephaly, variably associated with eye defects (retinal arterial tortuosity, Axenfeld-Rieger anomaly, and cataract) and systemic findings (kidney involvement, muscle crumps, cerebral aneurysms, Raynaud phenomenon, cardiac arrhythmia, and hemolytic anemia)[4]. To date, seven patients with a COL4A1-related disorder in association with hemolytic anemia have been reported. In 2013, Yoneda et al. reported that five among fifteen patients with COL4A1-related disorder had hemolytic anemia[5], indicating that hemolytic anemia may be one of the related features of COL4A1-related disorder. Interestingly, five patients showed improvement of anemia, with the longest at 6 months of age. In 2016, Tomotaki et al. reported a male infant with COL4A1-related disorder with severe hemolytic jaundice. His anemia improved after the red cell transfusion on day 29 without recurrence[6]. Maisonneuve et al. reported a fetal case with severe anemia in association with cerebral ischemohemorrhagic damage revealed by ultrasonography, in whom a de novo COL4A1 mutation was identified[7]. The clinical and hematological characteristics identified in this study are similar to those in previous reports[5,6]. The present four patients had severe jaundice and/or progressive anemia from birth, although there was no family history of anemia and jaundice. Three patients (Cases 2, 3, and 4) had icterus gravis neonatum and received phototherapy. Case 1 received blood transfusion seven times. These hematological features were almost certainly derived from COL4A1 mutations. COL4A1 encodes COL4A1 (α1 chain), which consists of an amino-terminal 7S domain, a triple-helix forming collagenous domain, and a carboxyl-terminal noncollagenous domain. The triple-helix forming collagenous domain consists of glycine-X-Y amino acid repeats, which are essential for the formation of type IV collagen protein[8]. COL4A1 forms a triple-helical structure with COL4A2 (α2 chain) by combining as heterotrimers with a 2:1 stoichiometry (alpha1-alpha1-alpha2), forming the sheet-like network[9]. The four COL4A1 variants identified in this study result in the substitutions of glycine for another amino acid residue in one of the glycine-X-Y repeats. The amino acid position of the mutation identified in Case 4, p.Gly948Asp, was the same as Case 4 reported by Yoneda et al., p.Gly948Ser, who did not show hemolytic anemia. The same amino acid of p.G785V identified in Case 1 was also affected in the case previously reported (p.G785E), with intrauterine stroke and anterior segment dysgenesis[10]. The mechanisms of hemolytic anemia in patients with COL4A1-related disorder have not yet been established. However, some proposed explanations have been considered. One explanation is that dysfunction of basement membranes leads to red cell destruction through the vasculature or reticuloendothelial system and effective transmigration of red cells or erythroid progenitor cells. Janowska-Wieczorek et al. reported that peripheral blood CD34+ cells strongly express collagen type IV degrading gelatinases, matrix metalloproteinases-2 (MMP-2) and MMP-9[11]. They suggested that type IV collagens expressed in bone marrow sinusoidal basement membranes influence the transmigration of blood progenitor cells. Infantile hemolytic anemia observed in four patients with COL4A1 variants spontaneously improved later. Morphological findings of the peripheral blood smear, such as schiozocytes and poikilocytes, were observed in peripheral blood smears in two patients. Transient hemolytic anemia and abnormal erythrocyte morphology resemble the findings of hereditary elliptocytosis during infancy. Transient hemolysis may depend on the development and growth of skeletal and nonskeletal red cell components. It has been reported that free 2,3-diphosphoglycerate (DPG), presented in neonatal RBCs as a consequence of diminished binding to fetal Hb, may render HE susceptible to in vivo fragmentation[12]. The developmental switch from fetal to adult hemoglobin, by diminishing available free 2,3-DPG, may explain the abatement of hemolytic anemia that accompanies maturation. In conclusion, COL4A1-related disorder should be listed as one of the differential diagnoses when we encounter infants with undiagnosed hemolytic anemia and congenital malformations of the brain. We consider that permanent management for hemolytic anemia is not necessary for patients with COL4A1-related disorders. Further studies are required to clarify how COL4A1 mutations are involved in anemia.
  11 in total

1.  COL4A1 Mutation in a Neonate With Intrauterine Stroke and Anterior Segment Dysgenesis.

Authors:  Shaheen Durrani-Kolarik; Kandamurugu Manickam; Bernadette Chen
Journal:  Pediatr Neurol       Date:  2016-04-24       Impact factor: 3.372

2.  Severe Hemolytic Jaundice in a Neonate with a Novel COL4A1 Mutation.

Authors:  Seiichi Tomotaki; Hiroshi Mizumoto; Takayuki Hamabata; Akira Kumakura; Mitsutaka Shiota; Hiroshi Arai; Kazuhiro Haginoya; Daisuke Hata
Journal:  Pediatr Neonatol       Date:  2014-05-23       Impact factor: 2.083

3.  Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly.

Authors:  Douglas B Gould; F Campbell Phalan; Guido J Breedveld; Saskia E van Mil; Richard S Smith; John C Schimenti; Umberto Aguglia; Marjo S van der Knaap; Peter Heutink; Simon W M John
Journal:  Science       Date:  2005-05-20       Impact factor: 47.728

4.  Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane.

Authors:  A Janowska-Wieczorek; L A Marquez; J M Nabholtz; M L Cabuhat; J Montaño; H Chang; J Rozmus; J A Russell; D R Edwards; A R Turner
Journal:  Blood       Date:  1999-05-15       Impact factor: 22.113

5.  Phenotypic spectrum of COL4A1 mutations: porencephaly to schizencephaly.

Authors:  Yuriko Yoneda; Kazuhiro Haginoya; Mitsuhiro Kato; Hitoshi Osaka; Kenji Yokochi; Hiroshi Arai; Akiyoshi Kakita; Takamichi Yamamoto; Yoshiro Otsuki; Shin-ichi Shimizu; Takahito Wada; Norihisa Koyama; Yoichi Mino; Noriko Kondo; Satoru Takahashi; Shinichi Hirabayashi; Jun-ichi Takanashi; Akihisa Okumura; Toshiyuki Kumagai; Satori Hirai; Makoto Nabetani; Shinji Saitoh; Ayako Hattori; Mami Yamasaki; Akira Kumakura; Yoshinobu Sugo; Kiyomi Nishiyama; Satoko Miyatake; Yoshinori Tsurusaki; Hiroshi Doi; Noriko Miyake; Naomichi Matsumoto; Hirotomo Saitsu
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

6.  Modulation of erythrocyte membrane mechanical stability by 2,3-diphosphoglycerate in the neonatal poikilocytosis/elliptocytosis syndrome.

Authors:  W C Mentzer; T A Iarocci; N Mohandas; P A Lane; B Smith; J Lazerson; T Hays
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

Review 7.  Mammalian collagen IV.

Authors:  Jamshid Khoshnoodi; Vadim Pedchenko; Billy G Hudson
Journal:  Microsc Res Tech       Date:  2008-05       Impact factor: 2.769

8.  Managing the Unusual Causes of Fetal Anemia.

Authors:  Emeline Maisonneuve; Imane Ben M'Barek; Thierry Leblanc; Lydie Da Costa; Stéphanie Friszer; Françoise Pernot; Pauline Thomas; Vanina Castaigne; Cécile Toly N'Dour; Agnès Mailloux; Anne Cortey; Jean-Marie Jouannic
Journal:  Fetal Diagn Ther       Date:  2019-09-10       Impact factor: 2.587

9.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

Review 10.  COL4A1 and COL4A2 mutations and disease: insights into pathogenic mechanisms and potential therapeutic targets.

Authors:  Debbie S Kuo; Cassandre Labelle-Dumais; Douglas B Gould
Journal:  Hum Mol Genet       Date:  2012-08-21       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.